Vascular Impact of Omega-3 in Metabolic Syndrome (CARDIOMEGA)

University Hospital, Rouen

Status

Completed

Conditions

Essential Hypertension

Metabolic Syndrome

Treatments

Dietary Supplement: omega-3 from vegetal origin

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01566188

2010/010 HP

Details and patient eligibility

About

The overall aims of the present project are to investigate the impact of a nutritional approach based on omega-3 from vegetal origin on vascular function in hypertension associated with metabolic syndrome.

Enrollment

95 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female and male patients with treated essential hypertension (blood pressure values<140/90 mmHg under antihypertensive treatment).
Presence of at least two of the following criteria of the metabolic syndrome: abdominal girth >102 cm in men or >88 cm in women, HDL-C<0.4 g/L in men or <0.5 g/L in women, fasting triglyceride >1.5 g/L (or specific treatment for these lipid abnormalities), fasting glucose >1.10 g/L.

Exclusion criteria

Secondary hypertension, myocardial infarction, coronary artery disease, cerebrovascular disease, stroke or transient ischemia, cardiac failure, diabetes (or fasting glucose>1.26 g/L) or renal failure (MDRD < 50 ml/min)
Severe hypercholesterolemia (total cholesterol > 2.5 g/l), alcohol or drug abuse, toxicomania, or clinically significant abnormalities in other current biological parameters.